Key Points Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522. Shares of Vertex Pharmaceuticals(NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. It posted adjusted earnings of $1.24 billion, or $4.76 per share, up from $1.05 billion, or $4.06 per share, in the prior-year period. However, both top- and bottom-line numbers missed the consensus Wall Street estimates. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » In addition, Vertex revealed that it has temporarily paused the multiple ascending dose portion of its phase 1/2 study evaluating experimental messenger RNA (mRNA) therapy VX-522 in treating cystic fibrosis (CF). The company didn't provide any details, stating only that there was a "tolerability issue."Image source: Getty Images. Putting Vertex's Q1 news into context Vertex's disappointing Q1 results were primarily due to what the company called "an expected revenue decline in Russia." Sales in the country have been hurt by copycat versions of its CF therapies. However, Vertex believes the issue in Russia "is a limited and isolated matter." The company is in the early stages of launching two new drugs, CF therapy Alyftrek and non-opioid pain medication Journavx. As sales pick up for these drugs, Vertex should deliver much stronger growth. What about the clinical pause for VX-522? It's too soon to know what will happen. Importantly, though, Vertex's already-approved therapies treat the vast majority of CF patients. VX-522 targets roughly 5,000 or so patients who can't be helped by the company's CFTR modulators. Is Vertex stock a buy? Vertex's share price is still in positive territory year to date despite today's pullback. I think the biotech stock remains an excellent long-term pick because of the growth prospects for Alyftrek and Journavx as well as the tremendous potential for its pipeline programs. Should you invest $1,000 in Vertex Pharmaceuticals right now? Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Story Continues Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $611,589!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $697,613!* Now, it’s worth notingStock Advisor’s total average return is894% — a market-crushing outperformance compared to163%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why Vertex Pharmaceuticals Stock Is Sinking Today was originally published by The Motley Fool View Comments
Why Vertex Pharmaceuticals Stock Is Sinking Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...